Stop STALLING Act
Official title: A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
What Do You Think?
How would you vote?
Vote to see the result.
What Happened in Congress?
Not yet voted on the floor.
Where the Bill Stands
- Introduced, done
- Committee, done
- Floor Vote, current stage
- Outcome, not yet
What This Bill Does
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Sponsors
Related Documents
Timeline
- SenateCommittee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- SenateCommittee on the Judiciary. Ordered to be reported without amendment favorably.
- Library of CongressIntroduced in Senate
- SenateRead twice and referred to the Committee on the Judiciary.
- Introduced
- Committee
Comments
Comments with insults, hate speech or personal information are removed.